Mogamulizumab: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Mogamulizumab. Educational only — not medical advice.
Labeled uses
POTELIGEO is indicated for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after at least one prior systemic therapy.
Source: FDA labeling via NIH DailyMed (set e53960ab…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.